TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma

NCT04217473 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
17
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

TILT Biotherapeutics Ltd.